INCY Incyte
- 53.760
- +0.670+1.26%
- 53.930
- +0.170+0.32%
Incyte News
Incyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Q1 2024 Insight Enterprises Inc Earnings Call
Incyte to Present at Upcoming Investor Conference
Incyte (NASDAQ:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas. The presentation will be webcast live
Incyte's Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip
Incyte Price Target Cut to $80.00/Share From $88.00 by TD Cowen
Incyte Price Target Cut to $80.00/Share From $88.00 by TD Cowen
Goldman Sachs Adjusts Price Target on Incyte to $60 From $63
Incyte (INCY) has an average outperform rating and price target range of $52 to $88, according to analysts polled by Capital IQ. Price: 53.57, Change: +1.52, Percent Change: +2.92
Truist Securities: Reiterates Incyte's (INCY.US) rating and adjusted from buy to buy rating, target price adjusted from $84.00 to $83.00.
Truist Securities: Reiterates Incyte's (INCY.US) rating and adjusted from buy to buy rating, target price adjusted from $84.00 to $83.00.
Truist Securities Reiterates Buy on Incyte, Lowers Price Target to $83
Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:INCY) with a Buy and lowers the price target from $84 to $83.
Incyte Is Maintained at Market Perform by BMO Capital
Incyte Is Maintained at Market Perform by BMO Capital
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)
Incyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 -0.1% BMO Capital $56 → $52 Maintains Market Perform 04/24/2024 61.38% Oppenheimer $92 → $84 Ma
BMO Capital Adjusts Incyte Price Target to $52 From $56
Incyte (INCY) has an average rating of outperform and price targets ranging from $52 to $88, according to analysts polled by Capital IQ.
RBC Capital Reaffirms Their Hold Rating on Incyte (INCY)
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)
Unusual Options Activity: XP, INCY and Others Attract Market Bets, XP V/OI Ratio Reaches 181.8
EST Apr 30th Closing Delivery - In the last three hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends
Truist Securities Trims Incyte's Price Target to $83 From $84, Buy Rating Maintained
Incyte (INCY) has an average rating of outperform and price targets ranging from $58 to $92, according to analysts polled by Capital IQ. Price: 51.55, Change: -1.01, Percent Change: -1.92
Earnings Call Summary | Incyte(INCY.US) Q1 2024 Earnings Conference
The following is a summary of the Incyte Corporation (INCY) Q1 2024 Earnings Call Transcript:Financial Performance:Incyte Corp saw a total revenue growth of 9% in Q1 2024 compared to the previous year
Incyte Misses Quarterly Profit on Weak Sales of Lead Drug
Research Alert: CFRA Maintains Buy View On Shares Of Incyte Corporation
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our target price by $4 to $61,
Incyte's Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed
Incyte (INCY) shares were nearly 1% higher in recent early Tuesday trading after the company reported Q1 non-GAAP earnings of $0.64 per diluted share, up from $0.37 a year earlier. Analysts polled by
Analysis
Price Target
No Data
